Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
5.4
24.55%
40%
—
298.20%
80%
—
5 Years
Score5.4
Net Growth24.55%
Net Trend40%
Net Income Consistency—
Rev Growth298.20%
Rev Trend80%
Revenue Consistency—
Eton Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 39K to $ 79M and net income went from -$ 27M to -$ 4M. Revenue increased in 4 of those 5 years; net income in 2.
Eton Pharmaceuticals Inc currently holds a 5-year HDB Score of 5.4 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 41.58 | — |
1 Year2025-08-12 | $ 17.32 | 140.07% |
5 Years2021-08-12 | $ 4.54 | 9x |
All Time2018-11-13 | $ 6.25 | 6x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2018-11-13 |
|---|---|---|---|---|
| Price | $ 41.58 | $ 17.32 | $ 4.54 | $ 6.25 |
| Return | — | 140.07% | 9x | 6x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 86M | -$ 1M | $ 19M |
| 2025 | $ 79M | -$ 4M | $ 25M |
| 2024 | $ 39M | -$ 3M | $ 14M |
| 2023 | $ 31M | -$ 936K | $ 21M |
| 2022 | $ 21M | -$ 9M | $ 16M |
| 2021 | $ 21M | -$ 1M | $ 14M |
| 2020 | $ 39K | -$ 27M | $ 21M |
| 2019 | $ 959K | -$ 18M | $ 12M |
| IPO2018 | $ 0.00 | -$ 12M | $ 26M |
Explore beyond ETON
You're looking at Eton Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
